Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Early phase 2 data for retatrutide, published in the New England Journal of Medicine in 2023, showed weight loss of up to about 24% over 48 weeks, with additional improvements in fasting glucose and insulin sensitivity
That only a numerical difference is observed here is most likely due to the low number of mice available in the present study
Pain varies by individual
And the two companies hinted that Wegovy is just the start of their partnership
EClinicalMedicine 58 , 101882 (2023)
US$ 22.28
US$ 29.45
US$ 24.04
US$ 21.76
